SCHEMBL23463560

SCHEMBL23463560

CCc1ccc(Cc2ccccc2C(C)(C)C)c(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 1/20 0.44
TAOK1 Q7L7X3 1/20 0.37
TAOK3 Q9H2K8 1/20 0.37
LTA4H P09960 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2A6 P11509 1/20 0.36
IDO1 P14902 2/20 0.36
PDK2 Q15119 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
MAOB P27338 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ATM Q13315 1/20 0.34
SIGMAR1 Q99720 2/20 0.34
CNR1 P21554 1/20 0.34
AR P10275 2/20 0.33
EPHX2 P34913 1/20 0.33
PPARG P37231 1/20 0.33
DHFR P00374 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27408304 0.83 TP53 (0.42) LTA4HCYP1A2CYP2A6PDK2SLC6A4
SCHEMBL2973658 0.82 HSPA5 (0.56) HSPA5CYP1A2CYP2A6SLC6A2SLC6A4
SCHEMBL12834802 0.78 FFAR4 (0.40) HSPA5TAOK1TAOK3CYP1A2CYP2A6
SCHEMBL13863236 0.77 HSPA5 (0.42) HSPA5CYP1A2CYP2A6IDO1PDK2
SCHEMBL5435016 0.76 ALDH1A1 (0.48) HSPA5CYP1A2IDO1KDM4EALDH1A1
SCHEMBL12114208 0.74 S1PR1 (0.37) CYP1A2CYP2A6IDO1PDK2SLC6A2
SCHEMBL19789643 0.73 PDE3B (0.47) HSPA5CYP1A2CYP2A6IDO1PDK2
SCHEMBL23865007 0.73 ESRRG (0.41) HSPA5CYP1A2SIGMAR1
SCHEMBL20882009 0.72 IDO1 (0.44) LTA4HCYP1A2IDO1SLC6A2SLC6A4
SCHEMBL26011551 0.71 POLQ (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021105857-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NOVARTIS AG (CH) 2021-06-03 WO disclosed